Table 1.

Demographics and clinical data of the sample (n = 24). Abbreviations: M: male; NPS: new/novel psychoactive substance.

Sex, M	19 (79.2)
Age, years	29.4 ± 7.5 (19–46)
Substance abused
Alcohol	9 (37.5)
Cocaine	11 (45.8)
Cannabis	11 (45.8)
Methamphetamine	1 (4.2)
Ketamine	1 (4.2)
NPS	1 (4.2)
Polysubstance users	10 (41.7)
Diagnosis
Substance-induced psychosis	18 (75)
Schizoaffective disorder	6 (25)
Coexisting diagnosis
Personality disorders: - Personality disorder NAS - Schizoid personality disorder - Schizotypal personality disorder	4 (16.7) 2 (8.3) 1 (4.2) 1 (4.2)
Brexpiprazole dosage (mg)	2.3 ± 0.9 (1–4)
Psychotropics other than brexpiprazole
Antipsychotics	Olanzapine 15–20 mg/day, 2 (8.3) Promazine 40–100 mg/day, 2 (8.3) Quetiapine 100 mg/day, 1 (4.2)
Antidepressants	Trazodone 50–220 mg, 3 (12.5) Sertraline 50 mg, 2 (8.3) Paroxetine 20 mg, 1 (4.2) Vortioxetine 10 mg, 1 (4.2)
Mood stabilizers	Valproate 600–1500 mg/day, 6 (25) Lamotrigine 300 mg/day, 1 (4.2) Gabapentin 900–1600 mg/day, 4 (16.7) Pregabalin 150–450 mg/day, 2 (8.3) Lithium sulfate 83 mg/day, 1 (4.2) Lithium carbonate 600 mg/day, 1 (4.2)
Benzodiazepines and Z-drugs	Lorazepam 7.5 mg/day, 1 (4.2) Clonazepam 2.5 mg/day, 1 (4.2) Delorazepam 3–10 mg/day, 3 (12.5) Diazepam 7–22 mg/day, 3 (12.5) Zolpidem 10 mg/day, 1 (4.2)
Others	Methadone 55 mg/day, 1 (4.2) Baclofen 35 mg/day, 1 (4.2)

Data are presented as n (%), means ± SDs, and ranges, as appropriate.